Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 93Small Cell Lung Carcinoma 74Neuroblastoma 44Carcinoma, Ovarian Epithelial 43Fallopian Tube Neoplasms 41Lung Neoplasms 39Neoplasms 29Uterine Cervical Neoplasms 26Leukemia 20Brain Neoplasms 18Leukemia, Myeloid, Acute 17Recurrence 16Sarcoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasm Metastasis 13Lymphoma 12Central Nervous System Neoplasms 12Retinoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Sarcoma, Ewing 10Unspecified Adult Solid Tumor, Protocol Specific 8Neuroectodermal Tumors, Primitive, Peripheral 8Myelodysplastic Syndromes 8Medulloblastoma 8Endometrial Neoplasms 8Burkitt Lymphoma 8Lymphoma, Follicular 7Leukemia, Myelomonocytic, Chronic 7Blast Crisis 7

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Solid Tumors × Topotecan × Clear all
NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

AstraZeneca

Phase 1 Completed
48 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡